Precigen reports full year 2023 financial results and business updates

–   significant progress made in the development of the prgn-2012 adenoverse immunotherapy for the treatment of rrp; precigen plans to submit a bla under an accelerated approval pathway in the second half of 2024; ramping up commercial readiness activities for a potential launch in 2025 – –   precigen's prgn-2012 received the first breakthrough therapy designation and accelerated approval pathway from the fda for the treatment of rrp – –   precigen received ind clearance for a randomized phase 2 study of prgn-2009 adenoverse immunotherapy in combination with pembrolizumab in hpv-associated recurrent/metastatic cervical cancer; study now active and recruiting patients – –   interim data from the ongoing phase 1b study of prgn-3006 ultracar-t in relapsed/refractory aml anticipated in the second half of 2024 – –   preliminary data from the phase 1 study of prgn-3007 next generation ultracar-t in ror1+ advanced cancers anticipated in the second half of 2024 – –   cash, cash equivalents, short-term and long-term investments totaled $62.9 million as of december 31, 2023 – –   continued focus on cost containment resulted in a reduction in sg&a costs of 16% for the twelve months ended december 31, 2023, compared to the prior year period – germantown, md. , march 19, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2023 financial results and business updates.
PGEN Ratings Summary
PGEN Quant Ranking